Operational Summary
for the Fiscal Year Ended March 31, 2021
May 12, 2021
Mitsubishi Chemical Holdings Corporation
Table of Contents
Consolidated Financial Statements for FY2020
Statements of Operations
Sales Revenue and Core Operating Income by Business Segment
Analysis of Core Operating Income
Overview of Business Segments
Special Items
Cash Flows
Statements of Financial Positions
FY2021 Forecasts
Business Segments : Changes from Fiscal 2020
Business Segment Information
Statement of Operations
Sales Revenue and Core Operating Income
Dividend Forecast
Page No. | References 1 |
Number of Subsidiaries and Affiliates and | |
5 | Overseas Sales Revenue and Core Operating |
Income | |
6 | Statements of Operations [Quarterly Data] |
7 | Sales Revenue and Core Operating Income |
by Business Segment [Quarterly Data] | |
8 | Core Operating Income (Loss) by Business |
Segment [New Business Segment basis] | |
- Special Items [Quarterly Data]
Capital Expenditure, Depreciation & Amortization, - R&D Expenses, and Number of Employees by Business Segment
- Trend of Performance
Page No. Trend of Financial Position
16 | References 2 |
18 Consolidated financial results for the Fiscal Year Ended March 31, 2021 (MTPC)
19
20
21
Page No.
23
24
25
26
27
28
29
30
Page No.
32
Mitsubishi Chemical Holdings Corporation has adopted IFRS starting with FY2016 1Q. | 2 |
List of Abbreviations
FY2021 | April 1, 2021 - March 31, 2022 | |
1st Half (1H): | April 1, 2021 - September 30, 2021 | |
2nd Half (2H): | October 1, 2021 - March 31, 2022 | |
FY2020 | April 1, 2020 - March 31, 2021 | |
1st Quarter (1Q): | April 1, 2020 - June 30, 2020 | |
2nd Quarter (2Q): | July 1, 2020 - September 30, 2020 | |
3rd Quarter (3Q): | October 1, 2020 - December 31, 2020 | |
4th Quarter (4Q): | January 1, 2021 - March 31, 2021 | |
1st Half (1H): | April 1, 2020 - September 30, 2020 | |
2nd Half (2H): | October 1, 2020 - March 31, 2021 | |
FY2019 | April 1, 2019 - March 31, 2020 | |
MCHC | Mitsubishi Chemical Holdings Corporation | |
MCC | Mitsubishi Chemical Corporation | |
MTPC | Mitsubishi Tanabe Pharma Corporation | |
LSII | Life Science Institute, Inc. | |
NSHD | Nippon Sanso Holdings Corporation |
3
Core Operating Income (Loss) by Business Segment
[Quarterly Data]
(Billions of Yen)
100.0
77.6 | ||||
80.0 | ||||
70.1 | 61.1 | |||
60.7 | ||||
59.0 | ||||
60.0 | ||||
49.3 | 50.2 | |||
39.6 |
40.0
20.0
13.8 15.0
0.0
(20.0)
3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | ||||
FY2018 | FY2019 | FY2020 | |||||||||||
Performance Products | Chemicals | Industrial Gases | Health Care | Others | |||||||||
4
Consolidated Statements of Operations
Exchange Rate (¥/$) | 106.3 | 105.6 | 105.9 | 109.0 | (3.1) | (3%) | ||||
Naphtha Price (¥/kl) | 27,600 | 35,000 | 31,300 | 42,900 | (11,600) | (27%) | ||||
(Billions of Yen) | ||||||||||
FY2020 | FY2019 | Difference | ||||||||
1H | 2H | % | ||||||||
Sales Revenue | 1,504.8 | 1,752.7 | 3,257.5 | 3,580.5 | (323.0) | (9%) | ||||
Continuing | ||||||||||
Core Operating Income *1 | 54.6 | 120.1 | 174.7 | 194.8 | (20.1) | (10%) | ||||
Special Items | (82.7) | (44.5) | (127.2) | (50.5) | (76.7) | |||||
Operating Income (Loss) | (28.1) | 75.6 | 47.5 | 144.3 | (96.8) | (67%) | ||||
*Operations | Financial Income/Expenses | (8.7) | (5.9) | (14.6) | (22.3) | 7.7 | ||||
Income Taxes | (3.1) | (7.1) | (10.2) | (52.3) | 42.1 | |||||
(Dividend included above) | [2.8] | [1.5] | [4.3] | [4.2] | [0.1] | |||||
(Foreign Exchange Gain/Loss included above) | [(0.4)] | [2.8] | [2.4] | [(3.7)] | [6.1] | |||||
Income (Loss) before Taxes | (36.8) | 69.7 | 32.9 | 122.0 | (89.1) | |||||
2 | ||||||||||
Net Income (Loss) from | ||||||||||
(39.9) | 62.6 | 22.7 | 69.7 | (47.0) | ||||||
Continuing Operations | ||||||||||
Net Income from Discontinued Operations *3 | - | - | - | 16.9 | (16.9) | |||||
Net Income (Loss) | (39.9) | 62.6 | 22.7 | 86.6 | (63.9) | |||||
Net Income (Loss) Attributable to Owners of the Parent | (49.7) | 42.1 | (7.6) | 54.1 | (61.7) | - | ||||
Net Income (Loss) Attributable to Non-Controlling Interests | 9.8 | 20.5 | 30.3 | 32.5 | (2.2) | |||||
*1 Share of profit of associates and joint ventures included. | 1.1 | 11.8 | 12.9 | 13.4 | (0.5) |
*2 Discontinued operations are not included.
*3 Figures for FY2019, include ¥15.8 billion from gain on share exchanges after tax.
Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non-recurring | |
factors (losses incurred by business withdrawal and streamlining, etc.). | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Mitsubishi Chemical Holdings Corporation published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2021 12:29:13 UTC.